Skip to content
Evigrade
MajorAntiepileptics. Carboxamide derivatives×Direct oral anticoagulants (factor Xa inhibitors)

Updated · Methodology

Mechanism

Edoxaban is a substrate of P-glycoprotein (P-gp), an efflux transporter. Carbamazepine is one of the P-gp inducers that may lower edoxaban plasma levels (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Carbamazepine may reduce plasma levels of direct oral anticoagulants, edoxaban included, which carries a risk of thrombosis (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The resulting anticoagulant levels may be too low for the intended effect (carbamazepine label, US Food and Drug Administration, FDA). Neither the labels nor the European Heart Rhythm Association table says how much edoxaban levels fall (EHRA 2021).

Symptoms

The main risk is thrombosis because edoxaban works less well (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In atrial fibrillation, this means ischaemic stroke or systemic embolism, and in venous thromboembolism a recurrence of deep vein thrombosis or pulmonary embolism. Signs include leg swelling and pain, sudden shortness of breath and chest pain, sudden weakness or numbness of an arm, a leg or one side of the face, and difficulty speaking.

Management

In general, avoid combining carbamazepine with edoxaban, as with rivaroxaban, apixaban and dabigatran (carbamazepine label, US Food and Drug Administration, FDA). If the combination cannot be avoided, monitor closely for signs and symptoms of thrombosis (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Use caution when edoxaban is combined with P-glycoprotein (P-gp) inducers, carbamazepine included (edoxaban SmPC, European Medicines Agency, EMA). The European Heart Rhythm Association table also requires caution for this pair, especially with polypharmacy or with two or more interactions that lower anticoagulant levels (EHRA 2021). The Spanish carbamazepine SmPC lists oral anticoagulants, edoxaban included, among the drugs whose doses are adjusted to clinical need (AEMPS). The dosing section of the edoxaban SmPC, however, lists only reasons to reduce the dose to 30 mg. It gives no specific dose for use with inducers (edoxaban SmPC, EMA). If edoxaban is stopped because of carbamazepine, keep anticoagulation continuous and switch to another anticoagulant as the edoxaban SmPC describes (EMA). With carbamazepine, the doses of warfarin and acenocoumarol are also adjusted to clinical need (carbamazepine SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Carbamazepine

Other interactions with Edoxaban